Cargando…

Employment and the role of personal factors among patients with ankylosing spondylitis: a Dutch cross-sectional case-control study

OBJECTIVES: To update the knowledge on employment and the role of mastery, a personal factor reflecting the level of control over life and disease, among Dutch patients with ankylosing spondylitis (AS) compared to general population subjects. METHODS: Data of persons ≤65 years participating in a Dut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Webers, Casper, Vanhoof, Laura, van Genderen, Simon, Heuft, Liesbeth, van de Laar, Mart, Luime, Jolanda, van der Heijde, Désirée, van Gaalen, Floris A, Spoorenberg, Anneke, Boonen, Annelies
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045712/ https://www.ncbi.nlm.nih.gov/pubmed/30018801 http://dx.doi.org/10.1136/rmdopen-2018-000680

Ejemplares similares

Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity
por: van Genderen, Simon, et al.
Publicado: (2016)

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
por: Webers, Casper, et al.
Publicado: (2018)

Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis
por: Ramiro, Sofia, et al.
Publicado: (2015)

Development, usability and acceptability of an integrated eHealth system for spondyloarthritis in the Netherlands (SpA-Net)
por: Webers, Casper, et al.
Publicado: (2019)

Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?: Data from the SPACE cohort
por: Rubio Vargas, Roxana, et al.
Publicado: (2016)

Impact of the COVID-19 pandemic on work productivity in patients with spondyloarthritis: results from the Dutch SpA-Net registry
por: Webers, Casper, et al.
Publicado: (2022)

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial
por: Molto, Anna, et al.
Publicado: (2021)

Do patients with ankylosing spondylitis adapt to their disease? Evidence from a ‘then-test’ in patients treated with TNF inhibitors
por: Essers, Ivette, et al.
Publicado: (2015)

Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life
por: Imkamp, Maike, et al.
Publicado: (2018)

Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort
por: Abawi, Ozair, et al.
Publicado: (2017)

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
por: Deodhar, Atul, et al.
Publicado: (2021)

No relationship between bone mineral density and syndesmophyte formation at the same level in the lumbar spine of patients with radiographic axial Spondyloarthritis
por: Marques, Mary Lucy, et al.
Publicado: (2020)

Geographical prevalence of family history in patients with axial spondyloarthritis and its association with HLA-B27 in the ASAS-PerSpA study
por: Boel, Anne, et al.
Publicado: (2022)

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018)

Determinants of the Physician Global Assessment of Disease Activity and Influence of Contextual Factors in Early Axial Spondyloarthritis
por: Hirano, Fumio, et al.
Publicado: (2022)

Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI
por: Essers, Ivette, et al.
Publicado: (2019)

Good construct validity of the CT Syndesmophyte Score (CTSS) in patients with radiographic axial spondyloarthritis
por: Stal, Rosalinde, et al.
Publicado: (2023)

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension
por: Deodhar, Atul, et al.
Publicado: (2021)

5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort
por: Madari, Queeny, et al.
Publicado: (2020)

Depression in ankylosing spondylitis and the role of disease-related and contextual factors: a cross-sectional study
por: Webers, Casper, et al.
Publicado: (2019)

Low-dose CT hounsfield units: a reliable methodology for assessing vertebral bone density in radiographic axial spondyloarthritis
por: Marques, Mary Lucy, et al.
Publicado: (2022)

Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis
por: Stal, Rosalinde, et al.
Publicado: (2022)

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction
por: Baraliakos, X, et al.
Publicado: (2016)

Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort
por: Nikiphorou, Elena, et al.
Publicado: (2021)

Inflammation, bone loss and 2-year bone formation at the same vertebra in axial spondyloarthritis: a multilevel MRI and low-dose CT analysis
por: Marques, Mary Lucy, et al.
Publicado: (2023)

Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)
por: Webers, Casper, et al.
Publicado: (2020)

Do fatty lesions explain the effect of inflammation on new syndesmophytes in patients with radiographic axial spondyloarthritis? Results from the SIAS cohort and ASSERT trial
por: Stal, Rosalinde, et al.
Publicado: (2023)

Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis
por: Li, Zhixiu, et al.
Publicado: (2021)

Clinical and genetic factors associated with radiographic damage in patients with ankylosing spondylitis
por: Nam, Bora, et al.
Publicado: (2023)

Evidence for a second ankylosing spondylitis-associated RUNX3 regulatory polymorphism
por: Vecellio, Matteo, et al.
Publicado: (2018)

Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades
por: Crossfield, Samantha S R, et al.
Publicado: (2021)

Functional Genomic Analysis of a RUNX3 Polymorphism Associated With Ankylosing Spondylitis
por: Vecellio, Matteo, et al.
Publicado: (2021)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
por: Braun, Juergen, et al.
Publicado: (2023)

Ankylosing spondylitis and mortality following hospitalised pneumonia: a population-based cohort study
por: Holland-Fischer, Mette, et al.
Publicado: (2020)

Development of a web-based decision aid for initiating biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in axial spondyloarthritis
por: Beckers, Esther, et al.
Publicado: (2023)

Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012
por: Huscher, Dörte, et al.
Publicado: (2015)

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hp38nsh2gvp9pgvf00erqff0v2